NEW INSIGHTS ON INHIBITOR DEVELOPMENT:IMPLICATIONS IN PUP MANAGEMENT
MONDAY 25 JULY, 2016 12:30 - 14:00Lunch box provided
Room 308 • West Building, level 3Orange County Convention Center 9400 Universal Blvd, Orlando, FL, USA
In conjunction with the XXXIInd congress of the World Federation of Hemophilia July 24-28, 2016, Orlando, USA
SYMPO
SIUM
Welcome to Orlando Louis Aledort, New York, USA
What is known today on mechanisms for inhibitor development Sébastien Lacroix-Desmazes, Paris, France
What can be learned from national registries and published data Jenny Goudemand, Lille, France
Results from a randomized controlled trial on inhibitor development in PUPs: the SIPPET study Flora Peyvandi, Milan, Italy
The pharmacoeconomical perspective: Inhibitor costs Lorenzo Giovanni Mantovani, Monza, Italy
Discussion
Round table on how recent findings can impact on PUPs management Chairs: Louis Aledort and Guy Young Patients organization perspective: Doctors’ perspective: Carmen Escuriola-Ettingshausen, Frankfurt - Mörfelden, Germany Robert Sidonio, Atlanta, USA
12:45 •13:00
13:00 •13:15
Chairs:
Louis ALEDORT Mount Sinai School of Medicine, New York, NY, USA
Guy YOUNG Children’s Hospital and University of Southern California Keck School of Medicine, Los Angeles, CA, USA
- EV
E-01
305-
3/20
16.
12:30 •12:35
12:35 •12:45
13:25 •13:30
13:30 •14:00
13:15 •13:25
NEW INSIGHTS ON INHIBITOR DEVELOPMENT: IMPLICATIONS IN PUP MANAGEMENT
PROGRAM